1. Rose G. The strategy of preventive medicine. Oxford: Oxford University Press, 1992.
2. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32–8.
3. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ 1981; 282: 1847–51.
4. Strachan D, Rose G. Strategies of prevention revisited: effects of imprecise measurement of risk factors on the evaluation of "high-risk" and "population-based" approaches to prevention of cardiovascular disease. J Clin Epidemiol 1991; 44: 1187–96.
5. Anderson KM, Odell PM, Wilson PW et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293–8.
6. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2–3.
7. National Service Framework for coronary heart disease: modern standards and service models. London: Department of Health, 2000.
8. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199–270.
9. Anderson KM, Wilson PW, Odell PM et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356–62.
10. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
11. Hense HW, Schulte H, Lowel H et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany – results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24: 937–45.
12. Brindle P, Emberson J, Lampe F et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003; 327: 1267–70.
13. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–6.
14. Corvol JC, Bouzamondo A, Sirol M et al. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Int Med 2003; 163: 669–76.
15. Gueyffier F, Boutitie F, Boissel JP et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Int Med 1997; 126: 761–77.
16. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
17. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
18. Shaper AG, Pocock SJ, Walker M et al. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ 1981; 283: 179–86.
19. Walker M, Shaper AG, Lennon L et al. Twenty year follow-up of a cohort based in general practices in 24 British towns. J Pub Health Med 2000; 22: 479–85.
20. Emberson JR, Whincup PH, Morris RW et al. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J 2003; 24: 1719–26.
21. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74.
22. Walker MK, Whincup PH, Shaper AG et al. Validation of patient recall of doctor-diagnosed heart attack and stroke: a postal questionnaire and record review comparison. Am J Epidemiol 1998; 148: 355–61.
23. Shaper AG, Phillips AN, Pocock SJ et al. Risk factors for stroke in middle aged British men. BMJ 1991; 302: 1111–5.
24. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for measurement error: the case of multiple covariates measured with error. Am J Epidemiol 1990; 132: 734–45.
25. Tomasson H. Risk scores from logistic regression: unbiased estimates of relative and attributable risk. Stats Med 1995; 14: 1331–9.
26. Efron B. The jackknife, the bootstrap and other re-sampling plans. Philadelphia: Society for Industrial and Applied Mathematics, 1982.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
28. Teo KK, Yusuf S, Pfeffer M et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360: 1037–43.
29. Law MR, Wald NJ, Morris JK et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
30. Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. J Pub Health Med 1998; 20: 441–8.
31. Tang JL, Armitage JM, Lancaster T et al. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects *Commentary: dietary change, cholesterol reduction, and the public health – what does meta-analysis add? BMJ 1998; 316: 1213–20.
32. Dowse GK, Gareeboo H, Alberti KG et al. Changes in population cholesterol concentrations and other cardiovascular risk factor levels after five years of the non-communicable disease intervention programme in Mauritius. Mauritius Non-communicable Disease Study Group. BMJ 1995; 311: 1255–9.
33. Clarke R, Frost C, Collins R et al. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. BMJ 1997; 314: 112–7.
34. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III – Analysis of data from trials of salt reduction. BMJ 1991; 302: 819–24.
35. Hooper L, Bartlett C, Davey Smith G et al. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ 2002; 325: 628.
36. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ 1988; 297: 319–28.
37. Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. The World Health Organization MONICA Project. Int J Epidemiol 1994; 23: 505–16.
38. McCarron P, Okasha M, McEwen J et al. Changes in blood pressure among students attending Glasgow University between 1948 and 1968: analyses of cross sectional surveys. BMJ 2001; 322: 885–9.
39. Boreham R, Erns B, Falaschetti E et al. Risk factors for cardiovascular disease. Health Survey for England, London: The Stationery Office, 1998.
40. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment. Heart 1999; 81: 380–6.
41. Murray CJL, Lauer JA, Hutubessy RCW et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003; 361: 717–25.
42. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 2003; 24: 1601–10.
43. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.

J.Emberson, P.Whincup, R.Morris, M.Walker,
S.Ebrahim